Chemo-free treatment is better than chemotherapy for a rare type of lymphoma
Author Information
Author(s): Chen Chao, Yin Jingjing, Duan Minghui, Wang Wei, Zhao Danqing, Wei Chong, Jia Congwei, Zhang Wei, Zhou Daobin, Zhang Yan
Primary Institution: Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Hypothesis
Is a chemo-free immunomodulatory regimen more effective than traditional chemotherapy for relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma?
Conclusion
Chemo-free regimens showed better treatment outcomes compared to traditional chemotherapy in patients with relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma.
Supporting Evidence
- Chemo-free regimens had a median time to next treatment that was not reached, indicating better disease control.
- Patients receiving chemo-free treatment had a 100% one-year overall survival rate compared to 57.1% in the chemotherapy group.
- Six patients in the chemo-free group achieved complete or partial remission without relapse.
Takeaway
This study found that using treatments without chemotherapy can work better for some patients with a rare type of lymphoma than using regular chemotherapy.
Methodology
The study retrospectively reviewed patients diagnosed with relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma between September 1997 and October 2020.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the small population size.
Limitations
The study is limited by its retrospective design and small sample size due to the rarity of the disease.
Participant Demographics
The median age of participants was 34 years, with 47.4% male and 84.2% presenting with B symptoms.
Statistical Information
P-Value
0.007
Statistical Significance
p=0.007
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website